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ABSTRACT
WILLIAM EVANS SISTRUNK: Histone Deacetylase Inhibitors and Breast Cancer
Metastasis: A Review and Exploration of HDACi(s) and other Chemotherapeutic Agents
(Under the direction of Dr. Yu-Dong Zhou and Dr. Dale G. Nagle)

The traditional perspective of Histone Deacetylase enzymes is focused around
their inherent epigenetic modification characteristics. While it is true that the histone
modification these enzymes exhibit play a role in cancer and related diseases, Histone
Deacetylase has a variety of non-histone targets. The non-histone targets include
microtubules and are of specific interest because of the microtubules’ role in cell line
differentiation, replication, apoptosis, and cancer metastasis. Using a variety of Histone
Deacetylase Inhibitors (HDACi) and other chemotherapeutic compounds, our research
group explored the HDACi effect on breast cancer cell lines. Our goal was to indicate the
presence of HDACi cell-line dependent cancer growth inhibition and to study the
hypothesized non-histone mechanism of microtubule modification in HDACi(s). The
experiment consisted of three parts: viability assay, clonogenic assay, and combination
assay which analyzed HDACi(s) possible synergistic character with microtubule
stabilizing compounds. The specific breast cancer cell lines used were MDA-MB-231
clones LM-4175 and BOM-1833, and MCF7-BOM. The results of our experiments
indicated that there was cell line dependent growth inhibition with the treatment of
HDACi(s). Specifically, MCF7-BOM showed to be more susceptible to treatment, and
this could be due to it being an estrogen receptor positive ER+ cell line. However, the
growth inhibition never reached complete inhibition and was most prominent at the
highest concentrations of HDACi(s). Higher concentrations of HDACi(s) also had the
most prominent effect on colony growth inhibition in the clonogenic assay. The
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combination assay had an interesting result indicating an antagonistic trend between
microtubule stabilizers and HDACi(s).
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Introduction: Breast Cancer
A profound statement that has resonated with me throughout my undergraduate
research came from a newly diagnosed breast cancer patient named Carol. She described
her first reaction like many of us would, “Why me?”; However, Carol’s next thought
was, “Why not me?” (37). Unfortunately, Carol is correct in that the incidence of breast
cancer does not discriminate among women. In other words, all have an absolute risk of
developing the disease in their lifetime. Currently, one out of every eight women develop
one of the many forms of breast cancer in their lifetime (15). That number is expected to
increase as screening methods advance and progress throughout the world. Some experts
predict that there will be 3.2 million new cases per year by 2050 compared to the
1,384,155 new cases registered in 2008 (29).
The emergence of cancer is simply a misprint of DNA. Imagine a cell as a
factory containing thousands of printing presses. The assembly of pages (DNA) copied
from the press (template strand DNA) is essentially the same process in which the body
replicates DNA. However, that is just one factory; the body has an estimated 10^13 or
thirty trillion cells in the body (17). Therefore, it is a question of when, not if,
cancerous errors will occur. The human body has complex mechanisms known and
unknown to correct these errors or apoptosis (self-terminate) corrupted cells. Despite
this, an accumulation of errors ranging from single digits to thousands of misprints can
develop into cancer. In the case of breast cancer, there are specific factors both non10

modifiable and modifiable that can increase the risk of developing the disease (15).
Non-modifiable factors or factors that cannot be controlled include age, race, genes, age
of menopause, breast density, body height, hormones, and prior history of breast biopsy
or benign tumors. Before the age of 30, women have a very small chance of developing
breast cancer. However, from the ages of 30 to 50 years of age, there is a dramatic
increase of disease incidence that remains elevated after the age of 50 (15). Race and
genetic factors are especially critical in addressing an individual’s chances of breast
cancer. Caucasian women over the age of 50 have an incidence rate of 351.9 per
100,000-compared to 292.2 per 100,000 African American women in the same age range
(15). One of the most well-known breast cancer genetic mutations is BRCA 1 and BRCA
2. According to the Center for Disease Control, 50 out of 100 women with these
mutations will develop breast cancer by the age of 70 (CDC). Thus, preemptive measures
such as Mastectomy (removal of breast tissue) become a desirable choice in these hyperpredisposed women. Physical and chemical characteristics of an individual such as breast
density, hormone levels, age of menopause, etc. can cause variability in breast cancer
incidence. For instance, research suggests that the delay in menopause results in a 3%
increase of breast cancer for every year of absence (15).
Unlike non-modifiable factors that are uncontrollable, modifiable factors such as
smoking, diet and exercise, environment, and hormone therapies can be controlled to
reduce the breast cancer risk. High alcohol consumption in an individual’s diet is the
most heavily correlated lifestyle factor associated with the risk of breast cancer (15).
According to one study, alcohol consumption is the primary cause in 4% of new breast
cancer diagnoses (27). Overall, modifiable risks other than alcohol consumption have a
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marginal increase in breast cancer incidence. However, it is important to consider that
avoiding known harmful modifiable factors can prevent a significant proportion of
postmenopausal breast cancer cases (28).
Although breast cancer is unfortunately common among women, the prognosis
is very heterogenous as each diagnosis depends on certain conditions. Tumor
morphology, genetic typing, and histological grade coalesce in outcomes ranging from
treatable to extremely malignant (29). Cancerous breast tumors are divided into several
categories including infiltrating ductal carcinoma, infiltrating lobular carcinoma,
tubular, mucinous, medullary, adenoid cystic carcinoma, and many other types (29).
Each type of breast cancer has unique characteristics determining prognosis. For
example, smaller tubular carcinomas are associated with a less advanced stage or
progression at presentation of disease compared to infiltrating ductal carcinomas (29).
The presence of estrogen receptors (ER positive) in a cancerous cell morphology
indicates favorable outcomes (1). Also, the presence of genes that code for proteins
such as HER2 (Human Epidermal Growth Factor Receptor 2) in tumor cells adds
another trait in which physicians and scientists must consider for treatment. In contrast
with ER positive breast cancer, Triple-Negative breast cancer (TNBC) is characterized
with poor outcomes and high rates of relapse (8). The TNBC cells lack HER2 protein
receptors, estrogen receptors, and progesterone receptors. In essence, the most effective
way to destroy tumors is to consider them unique individuals through personalized
medicine. This ideology centers around the mantra that there is both inter-heterogeneity
among tumor types and intra-heterogeneity within the tumor itself (4). Ultimately, the
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goal is to identify the breast cancer type and best course of treatment before the disease
is in its final stage.
What is final stage breast cancer? What aspect of the disease ultimately causes
death? These were two of my very first questions in the initial segment of research. The
simple answer is that metastasis or M-stage is the final progression of breast cancer.
Metastasis is the process in which cancerous cells spread to other parts of the body
through the blood or lymph circulatory systems. Furthermore, the new tumor formed is
of the same type as the primary tumor. For example, if cancerous cells spread from a
breast tumor to the brain, these cancerous cells are still breast tissue (26). Distant
metastases such as mentioned above (breast to brain) is the main cause of death in
breast cancer patients (5).
Metastatic or malignant tumors can cause death in a variety of ways depending
on where the secondary tumors form. For example, malignant tumors are highly
metabolic and can not only become strenuous to maintain but consume surrounding
normal cells to strengthen their viability. Metastasis also causes terminal complications
by interfering with bodily functions such as the immune system and circulatory system.
Secondary infections, strokes, and other serious medical conditions resulting from the
secondary tumor interference are the ultimate cause of death (30). Under these
circumstances, a patient that has progressed to M-stage breast cancer is at a much
higher risk than previous stages. Consequently, preventing the malignant
transformation of a primary tumor is a promising target for therapy. Under the guidance
of Dr. Yu-Dong Zhou and Dr. Dale G. Nagle, I along with my collaborators Mary
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Grace Stewart and Henry Nguyen have pursued drug therapies using Histone
Deacetylase Inhibitor (HDACi) class compounds to prevent malignant breast cancer.

Histone Deacetylase Inhibitors (HDACi)
The Human Genome Project represents a new era in the advancement of medicine.
Using the combined resources of collaborators from around the world, in 2003 the
entirety of the Human Genome was sequenced (25). In essence, the instruction manual
of every cell in the human body is now available to be studied and perhaps manipulated.
However, it is important to note that while some genes are constantly transcribed, many
remain silent depending on the cellular environment and cell type. The gatekeepers of
transcription are the histone proteins (3). Histones are proteins that have between 145147 DNA base pairs wrapped around the core histone protein. Each core histone protein
is globular in structure and consists of two histone protein subunits: H2A, H2B, H3, and
H4 (3). The histone is designed to be post-translationally modified by the acetylation of
lysine residues by histone acetylases (HATS). This function allows the histone to loosen
the DNA tightly wrapped around the core protein and enable transcription to occur (3).
Imagine being able to control the acetylation of histones and eventually
manipulate the phenotype of a cell without changing its inherent genotype. In 1977,
scientists were able to complete such a feat by converting a cancerous erythroleukemia
cell line into a non-dividing hemoglobin synthesizing cell using butyric acid, a histone
deacetylase inhibitor (HDACi) (11). In order to change the cell in such a drastic way, the
histone proteins must be denied the ability to be deacylated, which is the exact goal of

14

histone deacetylase inhibitors. The mechanism of HDACi consists of inhibiting the
histone deacetylase enzyme’s function of removing the acetyl group from lysine residues.
With the HDAC inhibited by the HDACi, the histone acetylases can freely function to
stimulate the transcription of DNA through the unwinding effect of the histone. Also, it
is especially important to note that HAT and HDAC enzymes have non-histone targets
in the cell. When HDACi(s) are introduced into the cell, the effects on both the histone
and non-histone proteins coalesce into increased cell apoptosis, decreased migration,
decreased proliferation, and cellular differentiation (32).

Figure 1 (20)

One pivotal question regarding the HDACi mechanism is: How do
noncancerous cells (and some cancerous) survive the hyperacetylation of histones that
cause the destruction/differentiation of many forms of cancer cells? While a concrete
answer is unknown, one study suggests that body cells have an innate response to
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downregulate histone acetylases during a period of hyperacetylation caused by HDACi
(12). This theory is supported by histone acetylation falling dramatically after cells
were removed from a HDACi rich environment. In other terms, the lack of HDACi
induced hyperacetylation in the new environment post-HDACi caused an
overcompensation of the innate cellular defense. How did this innate defense arise?
Interestingly, HDACi activity is observed in many natural products produced by
bacteria. Eukaryotic cells that were in the presence of these bacteria and thus the
HDACi developed this innate response over thousands of generations in order to
survive. The human body even has HDACi activity present in the large intestine where
bacteria are believed to act as a weapon against eukaryotic organisms competing for the
same resources (12).
Histone Deacetylase enzymes are a very diverse group of molecules affecting
many components of the cell and body. In fact, there are four classes each representing
numerous subtypes: HDAC class I, consisting of HDAC 1,2,3,8. HDAC class II(a),
consisting of HDAC 4,5,6, and 7. HDAC class II(b), consisting of HDAC 6 and 10.
HDAC class IV, contains HDAC 11 (10). While each HDAC subtype has many
functions, the most crucial to my research are HDAC 1, 2, and 6. HDAC 1 and 2 are
intricate in the processes of cell proliferation and apoptosis. The overexpression of
HDAC 1 and 2 are associated with many forms of cancer including breast, lung, and
classical Hodgkin’s lymphoma (2). HDAC 6 is mostly present in the cytoplasm and is a
target of α-tubulin. The HDAC 6 mechanism with chaperon protein Hsp90 is known to
increase the growth of some forms of prostate and breast cancer. HDAC 6 is also
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associated with oral squamous cell carcinoma and expression increases in advanced stage
cancers in comparison to early stage (2).
One of the non-histone targets of HDAC 6—as mentioned previously—is alphatubulin. Microtubules have a complex mechanism of elongation and degradation that
enable cells to be motile in their external and internal environment. The acetylation of αtubulin has a stabilizing effect that leads to long lived, less motile, and less dynamic
microtubules (6). In contrast, HDAC 6 upregulation causes the deacetylation of
microtubules that is associated with cell invasion and metastasis. Therefore, compounds
inhibiting HDAC 6 are promising potential therapeutic agents for preventing metastasis
in late stage cancers (6).
What is the current state of HDACi(s) in the clinical treatment of cancer? Four
HDACi compounds have been FDA approved: Vorinostat (SAHA), Romidepsin,
Panobinostat, and Belinostat. Vorinostat inhibits class I, II, and IV HDAC molecules and
is approved for treatment of Cutaneous T-cell Lymphoma (CTCL). Romidepsin inhibits
class I HDAC molecules and is approved for treatment of CTCL. Panobinostat inhibits
class I, II, and IV HDAC molecules and is approved for treatment of CTCL and multiple
Myeloma. Lastly, Belinostat inhibits class I, II, and IV HDAC molecules and is approved
for treatment of Peripheral T-cell Lymphoma (PTCL) (17). The common denominator for
each FDA approved HDACi(s) is that they are effective in the treatment of non-solid
tumors (Myeloma, Lymphoma). While this clinical use is promising, one of the most
exciting characteristics of HDACi(s) is its ability to work synergistically with other
chemotherapeutic agents (7). HDACi(s) in combination with other epigenetic modifiers,
reactive oxygen species, protease inhibitors, DNA damaging agents, and microtubule
17

stabilizers have increased chemotherapeutic effects. While numerous studies support the
synergistic effect, the mechanism is generally unknown (7).
In the experiments the research group conducted, we examined the relationship of
Histone Deacetylase Inhibitors and other chemotherapy agents on multiple breast cancer
cell lines. The purpose of the viability, combination, and other cell assays was to replicate
and further understand the therapeutic effect of HDACi(s) on breast cancer.

Histone Deacetylase Inhibitor Experiment
The experimental timeline and progression that has encompassed over two years
began in the fall of 2016 under the direction of Dr. Nagle and Dr. Zhou. The first section
was a seminar class that introduced new researchers to the many intricacies of breast
cancer and beyond. The second section was devising a research plan in order to
understand the effects of Histone Deacetylase Inhibitors on specific breast cancer cell
lines. The HDACi research plan consisted of background research, viability assay,
combination assay, and clonogenic assay. While it was a general goal to study all
HDACi(s), HDAC 6 inhibitors were of specific interest because of the non-histone
microtubule targets it influences. Therefore, microtubule stabilizers and destabilizers
were used in viability studies as well as in combination with HDACi(s) to study this
effect. Our general hypothesis stated HDACi(s) may exhibit cell-line dependent
inhibitory activity against breast cancer cells.
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MATERIALS AND METHODS
Background Research
In the spring of 2017, after the decision to pursue HDACi(s) with a concentration
of the anticancer effects of HDAC 6 inhibitors, the initial plan of research was to conduct
a background review on the topic. This process was completed in three steps: literature
review, survey known HDACi/chemotherapy compound data, and selection of cell
lines/compounds. Dr. Zhou emphasized the importance of literature review before
conducting our experiment in order to maximize our chances of originality in the field.
While it is difficult to produce new data because of the constant global competition,
literature review was helpful because we could determine what had been researched and
use that knowledge to focus on the selection of our topic. We learned that the role of
HDAC 1, 2, and 3 and the inhibition of these HDACs in the treatment of breast cancer
have been researched frequently in studies conducted over five years ago (22). However,
we also learned more about HDAC 6 and the HDAC 6 inhibitor’s role in microtubule
stability (6). Since HDAC 6 interacts with microtubules, Dr. Zhou suggested using an
HDAC 6 inhibitor in conjunction with paclitaxel and other microtubule stabilizers and
destabilizers. In essence, there could be a synergistic property associated with the
addition of HDAC 6 inhibitors with classic chemotherapy agents such as paclitaxel.
The next step of the background review was to survey known chemotherapy
compounds and their inhibitory effects on each cell line. This procedure was completed
using the National Cancer Institute Developmental Therapeutic Program named NCI-60
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Human Tumor Cell Line Screen. The NCI-60 cell line assay results function as a
database for the compound concentration needed to reach LC50 (LC50 is the lethal dose
in which 50% of cells are destroyed in a given amount of time) in a particular cell line. In
each compound our group was interested in, we would use the NCI-60 panel data to
determine the general concentrations needed to reach LC50 and in turn determine a
general guideline for the quantity of compound needed in our experiment.
Compounds were selected to fill five classes of HDACi(s) and microtubule
stabilizers/destabilizers: HDAC 1 and 2 inhibitors, HDAC 6 inhibitors, microtubule
stabilizers, microtubule destabilizers, and pan-HDAC inhibitors. Among the compounds
selected to fulfill these categories, further selections were based on logistics and
availability of the compound.
Compound Data
Drug Classification

Compound Name

Purchased from

Solubility/stock solution

HDACi 1 and 2

Romidepsin

Cayman

100 µM

HDACi 6

Ricolinostat

Selleck

10 mM

MT Stabilizer

Paclitaxel

Sigma

10 mM

Epothilone B

Selleck

10 mM

Colchicine

Sigma

100 µM

Vinblastine

Sigma

100 µM

Vorinostat (SAHA)

Cayman

10 mM

Panobinostat

Cayman

100 µM

MT Destabilizer

Pan-HDACi

Figure 2
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Molecular Structure

Romidepsin

Ricolinostat

Paclitaxel

Epothilone B

Colchicine

Vinblastine
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Vorinostat (SAHA)

Panobinostat

Figure 3

Preparation of HDACi and Chemotherapy Agent Dilution Plate
The chemotherapeutic agents were purchased from Cayman Chemical, SigmaAldrich, or Selleck Chemical. For our experiments, we set the stock solution
concentration of 10 mM or 100 µM for each compound. Specific amounts of DMSO
were added to each chemotherapeutic agent in order to configure the stock solution
concentrations from the variable factory purchased compound concentrations. Serum free
media was used to dilute the stock solutions to the highest tested concentration, and this
was set at 2x the final concentration of the mother plate. The mother plate was prepared
at 3.5x volume (of a single dose) because it was to be used on three SRB viability 96-well
plates. A 1:10 serial dilution was performed creating a dilution pattern as seen in the table
below (Top 10,3,1,.3,.1,.03,.01 μM Bottom). This process was completed in a stepwise
pattern. For example, in one dilution we siphoned 35 μL of 0.1 μM solution into a well of
315 μL of serum free medium which created 350 μL of diluted solution at 0.01 μM. Each
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dilution was calculated to have 350 μL of end product in each well.

Figure 4: Serial Dilution Example 96-Well Plate
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Breast Cancer Derived Cell Lines
The human breast cancer cell lines used in experimentation was MDA-MB-231,
MDA-MB-231 subtypes BOM clone 1833 (bone metastasis) and LM clone 4173 (lung
metastasis), and MCF7-BOM. MDA-MB-231 is a triple negative breast cancer that was
derived from a pleural effusion in a 51-year-old Caucasian female in the 1970’s (18).
MDA-MB-231 is an aggressive tumor with poor prognosis which commonly metastasizes
to the lung and bone to form secondary tumors. MDA-MB-231 BOM and LM are cell
lines derived from these secondary tumors and were first generated by Dr. J Massagué at
the Sloan Kettering Cancer Center (21). Our experiments acquired the specific MDAMB-231 clones BOM 1833 and LM 4175 from Dr. Konosuke Watabe at Wake Forest
University. MCF7 is an ER-positive breast cancer cell line that was originally derived
from a 69-year-old Caucasian female in the 1970’s (18). The MCF7-BOM cells that were
used in our experimentation are another product of bone secondary metastasis generated
in Dr. J Massagué’s lab at the Sloan Kettering Cancer Center (23). Our lab acquired
MCF7-BOM cells from Dr. Konosuke Watabe at Wake Forest University.
The MDA-MB-231 (BOM and LM) and MCF7-BOM cell lines were sustained in
DMEM/F12 media containing L-glutamine (Mediatech, Manassas, VA), enriched with
10% fetal bovine serum (FBS) (Hyclone, Logan, UT),50 units/mL of penicillin and 50
µg/mL streptomycin (Gibco, Grand Island, NY) were added, and the cells were
temperature controlled at 37 °C in an environment of 95% air/5% CO 2 (34).
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Sulforhodamine B (SRB) Viability Assay
The SRB viability assay procedure started after the 96-well master dilution plate
was created and the specific cell lines developed to the desired density. The SRB viability
assays are a rapid, relatively inexpensive, and reliable test to study the effects of
particular compounds on cell line proliferation (24). The first step of the process was to
trypsonize the cell cultures using 1 mL (Trypsin) and then wash the cells with 10 mL of
10% fetal bovine serum (FBS) media. The cells were then diluted with additional 10%
FBS media until a density of 3 million cells per mL of 10% FBS was reached using a
hemocytometer. Next, 100 µL of cell solution and 100 µL of media were seeded to each
well in the desired number of 96-well plates (depending on the specific trial
requirements) at a concentration of 30,000 cells per well. The plates were cultured at 37°
C within a humid environment of 95% air and 5% C02. The 96-well cell containing plates
were then infused with a specific amount of chemotherapy agent in the 96-well master
dilution plate. The combination chemotherapy agent/cell plates were incubated for 48
hours. After the incubation process was complete, 100 µL of media was withdrawn from
each well. The wells began the fixation process with the addition of 100 µL of 20%
trichloroacetic acid (TCA) and 1% PBS solution to each well. The fixed plates were
placed in the refrigerator for one hour at 4°C. After removal from the refrigerator, the
plates were washed with tap water four times and set aside to dry. Each well was then
stained using 100 µL of .4% SRB (w/v, 1% acetic acid) for 10 minutes at room
temperature. The plates were further washed with 1% acetic acid four times and set aside
to dry. Tris Base (100 µL of 10 mM) was added to each of the stained wells, and the
plates were lightly shaken for 10 minutes using the microplate genie. The plates were
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then read using the SpectaFlour plate and Magellen software at an absorbance range of
496-620 nm. The SRB dye binds to the basic amino acids present in the cell proteins
allowing for Magellan software to calculate the inhibition value. This inhibition value
was generated by the software using the total protein mass per well (flagged by the
SRB dye) which is proportional to the cell density of that cell.

Combination Assay
One of the main objectives of these series of experiments was to explore the
synergistic or possibly antagonistic effects of HDACi(s) and other chemotherapeutic
compounds. Therefore, a combination assay was conducted using a cross of HDACi
compounds and microtubule stabilizing chemotherapeutic agents’ paclitaxel and
epothilone B. The procedure of the combination assay was very similar to the viability
assays performed. The difference was the bidirectional compound addition where the
microtubule stabilizers (Taxol and epothilone) were added from left to right and the
HDACi(s) (romidepsin, ricolinostat, panobinostat) were added from top to bottom. The
specific HDACi(s) tested were chosen based on the range of HDACi activity they
exhibit. Romidepsin is a class 1 HDACi that showed strong and consistent activity in
our viability screening. Ricolinostat is a class 6 HDAC inhibitor and was selected
because of our interest in its specific effect on microtubule stabilization and
destabilization. Panobinostat was selected because it is a pan-HDACi, meaning it
inhibits all classes of HDAC. The concentration ranges for both HDACi(s) and
microtubule stabilizers were determined based on concentrations used in the National
Cancer Institute Database of both experimental and physiological relevance.
26

Combination
Assay

V
V

Romidepsin
V
V
V
V

V
V

Ricolinostat
V
V
V
V

V
V

Panobinostat
V
V
V
V
V
V

Taxol 0
nM ===>

0.001 µM

0.01
µM

0.1
µM

0.1
µM

1
µM

10 µM

0.0001
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0.001
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0.01
µM

0.1 µM

Taxol 10
nM ===>
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µM
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Figure 5: Combination Dilution 96-Well Plate

Clonogenic Assay
The Clonogenic assay is used in assessing the survivability of a cell line in the
presence of a cytotoxic agent. Essentially, the ability for a single cell to grow into a
colony under cytotoxic conditions (9). The number of six-well plates used was a total of
six: three for the BOM and three for MCF7-BOM cell lines. The first plate in each cell
line had two media control wells and four chemotherapeutic compound wells. The second
and third plates of each cell line had all six wells containing chemotherapeutic
compounds. The concentrations of the chemotherapeutic agents were based on
physiological relevance (low concentration) and cytotoxic potential (high concentration).
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Chemotherapeutic

Cytotoxic Potential

Compound

Physiological
Relevance

Vorinostat (SAHA)

10 µM

1.0 µM

Ricolinostat

10 µM

1.0 µM

Romidepsin

0.01 µM

0.001 µM

Panobinostat

0.1 µM

0.01 µM

Paclitaxel

1.0 µM

0.1 µM

Epothilone B

0.01 µM

0.001 µM

Colchicine

0.1 µM

0.01 µM

Vinblastine

0.1 µM

0.01 µM

Figure 6

The cells were seeded in a density of 3,000 cells per well, and six-well plates
were incubated for four hours at 37°C allowing the cells to adhere. After a period of 24
hours, the media solution was replenished with fresh FBS (10%) with antibiotics. This
incubation process was then conducted over ten days with fresh medium replenished
every five days. After the incubation period, the cells were fixed with methanol and
stained using crystal violet solution (1 mg/mL in 20% ethanol). Pictures of the final
Clonogenic assay product were taken on an iPhone XR.
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Results and Discussion
SRB Viability Assay
The results of the Sulforhodamine B viability assay reflect the percent inhibition
values of the chemotherapeutic agents tested on MDA-MB-231 BOM, MDA-MB-231
LM, and MCF7-BOM cell lines. The initial goal of viability testing was to acquire an
IC50 value (drug concentration where cell growth is inhibited by half of total inhibition).
However, while our results had significant inhibition, they never reached this value.
Instead, our group categorized each chemotherapeutic drug into a highest inhibitory
concentration category under the parameters of cell line, percent inhibition, and drug
concentration of highest inhibition. The highest inhibitory concentration results and
trends of the viability tests are located in the figures below. The graphs were configured
using prism GraphPad 8.

Highest Inhibitory Concentration
Chemotherapeutic

LM

BOM

MCF7-BOM

Agent

Con [ ]

% Inhibit

Con [ ]

% Inhibit

Con [ ]

% Inhibit

Vorinostat (SAHA)

10 µM

58

3 µM

24

10 µM

48

Ricolinostat

10 µM

51

10 µM

29

10 µM

42

Panobinostat

0.1 µM

52

0.1 µM

34

0.1 µM

29

Romidepsin

0.1 µM

50

0.1 µM

36

0.1 µM

46

Vinblastine

0.1 µM

38

0.1 µM

28

0.1 µM

16

Colchicine

0.1 µM

30

0.1 µM

22

0.1 µM

44

Epothilone B

0.1 µM

39

0.1 µM

31

0.1 µM

41

Paclitaxel

10 µM

47

10 µM

33

10 µM

47

Figure 7
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Figure 8
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In the Highest Inhibitory Concentration table, the cells that were highlighted
represent values in which the greatest growth inhibition was not at the highest
concentration of chemotherapeutic agent tested. However, in the case of epothilone B,
inhibition was relatively similar across all cell lines from the lowest to highest
concentration. The results were conflicting in the MDA-MB-231 BOM vorinostat
(SAHA) data. The first and second highest concentrations tested were relatively similar,
possibly indicating a plateau in inhibitory effect at these concentrations. Further testing
for both MDA-MB-231 BOM vorinostat (SAHA) and epothilone B SRB viability would
be ideal to further specify the data.
An interesting aspect of our results was the sensitivity of the MCF7-BOM cell
line compared to the MDA-MB-231 BOM and LM cell lines. There was a consistent
trend of MCF7-BOM being the most susceptible or a close second in every trial. This
could be due to the MCF7-BOM cell lines being estrogen receptor positive (ER+)
compared to the triple-negative cell lines of MDA-MB-231 BOM and LM. One previous
study found that HDACi enhances ER(+)-stress mediated cell death in some cancers (14).
That being said, one of the highest percent inhibition values was romidepsin, a HDAC 1
and 2 inhibitor, at 74% inhibition in the MCF-7 BOM cell line. Interestingly, the HDAC
6 inhibitor ricolinostat had the most effect on the MCF-7 BOM cell line with a sharp
slope. This finding could be promising as a higher drug concentration could lead to
increased cell growth inhibition. Overall, there is a clear (though somewhat small)
inhibitory effect of HDACi(s) on these specific breast cancer cell lines.
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Figure 9
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There was a second round of SRB viability testing conducted on the MDA-MB231 BOM cell line in order to replicate our findings in the first viability experiment and
to fine tune our laboratory skills in the viability procedure. In general, our results were
very similar to the original MDA-MG-231 BOM viability assay. The epothilone B assay
exhibited a high inhibition at both low and high concentrations, and the other drug assays
exhibited similar inhibitory effects. However, there were a few differences that are
noteworthy. First, the percent inhibition values were larger in general. These numbers
could be caused from a variety of reasons including the cell line being weakened
(stressed) to begin with and/or our lab technique was slightly superior in delivering the
chemotherapeutic agents. Second, romidepsin and panobinostat exhibited around 0%
inhibition at their highest concentration. This finding directly contradicts the first
viability experiment and is most likely an error in the lab. More testing is required to
clarify the contradiction of results.
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Clonogenic Assay
BOM

MCF-7 BOM

Figure 10
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The figures above represent two three-plate clonogenic assays on the MDA-MB231 BOM cell line and MCF-7 BOM. In a general visual comparision of the two plates,
relativly similar clonogenic inhibition occurred between the two cell lines. This tends to
suggest that there is relativly little cell line dependence in clonogenic inhibition between
the two cell lines. What is interesting is the difference between the physiologically
relevent concentration inhibition of HDACi(s) and the cytotoxic potential. In every
HDACi physiological (lower) concentration well, there was some form of colony growth.
On the other hand, cytotoxic potential concentrations of HDACi exhibited virtually
complete colony growth inhibition. The only other chemotherapuetic compounds that had
such inhibition were the microtubule stabilizers paclitaxel and epothilone B at both
physiological and cytotoxic relevence. This HDACi concentration dependent colony
growth inhibition could be due to the microtubule stabilizing or destabilizing effect
taking place at the cytotoxic potential concentration. In essence, the microtubule effect of
HDACi(s) (as suggested by previous studies) could be exhibiting the same properties as
epothilone B and paclitaxel (6). Overall, the clonogenic assay provided further evidence
of the inhibitory effects that HDACi(s) have on breast cancer cell lines. It also suggests
further avenues of research regarding HDACi(s) effect on microtubule destabilization or
stabilization.
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Combination Assay

36

Figure 11, 12, 13

The goal of the combination assays conducted was to determine the possible
synergistic or antagonistic effects associated with the combination of these
chemotherapeutic compounds. The results obtained were then compared to the US
National Cancer Institute’s Combination Almanac. This reference system provides
previous crosses of the compounds of interest in a variety of cell lines. However, the
crosses in the almanac are not necessarily the same as our experiment. Therefore, some
direct comparisons are not possible.
The combination assay represented in figure 11 is a cross between panobinostat
(pan-HDAC inhibitor), epothilone B, and paclitaxel in two different cell lines: MDAMB-231 BOM and MCF7-BOM. In comparing the two cell lines, there also was
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relatively little cell line dependent inhibition. There was only a slight variation in
magnitude where every trend is the same.
In both cell lines, the panobinostat-paclitaxel cross and the panobinostat-epothilone B
inhibition cross percent inhibition values were highest when panobinostat was at 0.001
µM across all ranges of microtubule stabilizer concentrations. In regard to the
synergistic or antagonistic characters of these compounds in combination, there is an
antagonistic relationship between panobinostat-paclitaxel and panobinostat-epothilone
B. This is evident because of the decrease in percent inhibition as the microtubule
stabilizer concentration increased along with the increase in concentration of HDACi.
The combination Assay represented in figure 12 is a cross between ricolinostat
(HDAC 6 Inhibitor), epothilone B, and paclitaxel. The same cell lines were used in
figure 12 as figure 11. In comparison between MDA-MB-231 BOM and MCF7-BOM,
there is no evidence of cell line dependent inhibition. After discussion within the
research group, we concluded that the graphs represented are abnormal. In both
paclitaxel-ricolinostat and epothilone B-ricolinostat crosses, the results at high
combination are sporadic and vary. This could be due to cell line stress, human lab
error, or an unknown factor. However, a general antagonistic trend can be seen in both
crosses as the microtubule stabilizer concentration increases and HDACi concentration
increases.
The combination assay represented in figure 13 is a cross between romidepsin
(HDAC 1 and 2 Inhibitor), epothilone B, and paclitaxel. The same cell lines were used
in figure 13 as figures 11 and 12. There is also a similar effect as seen in figures 11
and 12 in that there is no cell line dependent inhibition between MDA-MB-231 BOM
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and MCF7-BOM. In the paclitaxel-romidepsin cross, the highest inhibiting
combination of compounds were present at 0.001 µM across all ranges of paclitaxel.
There was also a strong antagonistic trend that increased when paclitaxel
concentrations were elevated and romidepsin concentrations were elevated. In this
particular cross, there had been previous data on the NCI Almanac reference tool.
According to the reference, both MCF7 and MDA-MB-231 cell lines showed an
antagonistic relationship (NCI). This provided some validation to our group as we
were able to compare similar research to our own data. The epothilone B-romidepsin
cross had the highest inhibition values at 0 µM romidepsin in high concentrations of
epothilone. It appeared that romidepsin and epothilone B had an antagonistic
relationship similar to previous trends of the other compound combinations. However,
these were some of the most antagonistic as there was a sharp decline in inhibition at
the highest concentrations of epothilone B and romidepsin.
Overall, there was an antagonistic trend with the increased concentrations of
microtubule stabilizers and HDACi(s). This was also supported by relevant data at the
NCI Combination Almanac. However, our data should be supplemented in the future
by a replicate number of n=3 compared to our n=2. There could be many possible
answers to why this antagonistic trend occurs. One answer could be a microtubule
destabilizing effect that is present in HDACi competing with the microtubule
stabilizing compounds. In order to answer this question, further research must be
conducted on HDACi(s) effect on microtubules.
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Conclusion
In reflecting on the analysis of the SRB viability assays, clonogenic assays, and
combination assays across a variety of cell lines, our hypothesis that histone
deacetylase inhibitors have cell line-dependent inhibition is supported. In the MDAMB-231 clones BOM-1833 and LM-4175 as well as MCF7-BOM breast cancer cell
lines, there was a variation in inhibitory effects in SRB viability testing. This could be
due to the presence of ER receptors. However, more research must be conducted and
higher concentrations should be tested in order to find the IC50 values of the
HDACi(s) tested. The clonogenic assay also provided evidence of HDACi tumor
growth inhibition. At the cytotoxic potential or highest concentration, HDACi(s) had a
great degree of colony growth inhibition. However, at physiologically relevant
concentrations, there was only mild inhibition. When HDACi(s) were combined with
the microtubule stabilizers epothilone B and paclitaxel, an antagonistic trend was
observed. Therefore, this combination may not be desired for chemotherapeutic
therapy. However, this evidence provides another step in understanding the nonhistone targets of HDACi(s) and their role in microtubule stabilization and
destabilization. In order to further this experiment, fluorescent labeling of
microtubules and other structure proteins would benefit the understanding of this
potential mechanism.
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